

# HIV Prevention Research at the International AIDS Conference

Vienna • 18-23 July 2010



The “roadmap” below provides information on sessions and events of interest for HIV prevention research advocates. For the most up-to-date version of the roadmap, visit <http://www.avac.org/aids2010>. Planning an event on a topic related to HIV prevention research? Email us the details at [avac@avac.org](mailto:avac@avac.org), and we’ll add it to the map. For more information on the conference visit <http://www.aids2010.org>. All session rooms, unless otherwise noted, are located within the conference venue: Reed Messe Wien, Messeplatz 1, Vienna.

[Session summaries and organizers are included where available.]

## BOOTHS AT THE CONFERENCE

### *Global Village Booth: Partners in Prevention Research*

**Details:** Booth number 637 in the Global Village

**Summary:** This is a community-focused booth where advocates from around the world can get important information on HIV prevention research and advocacy. The booth will feature a range of materials on HIV prevention, interactive learning panels on prevention research, and a place for networking and informal discussions among delegates and local community members.

**Organizer(s):** African Microbicides Advocacy Group, AVAC, Global Campaign for Microbicides, International AIDS Vaccine Initiative, International Rectal Microbicides Advocates, the New HIV Vaccine and Microbicide Advocacy Society

### *Exhibition Hall Booth: AVAC—Global Advocacy for HIV Prevention Research*

**Details:** Stand E-409 in the Exhibition Hall

**Summary:** This booth will feature a range of materials on HIV prevention, short presentations and a space for networking and informal discussions so advocates from around the world can gather to get information and discuss important issues related to HIV prevention research and advocacy.

### *Exhibition Hall Booth: FHI*

**Details:** Stand E-420 in the Exhibition Hall

### *Exhibition Hall Booth: Global HIV Vaccine Enterprise*

**Details:** Stand E-476 in the Exhibition Hall

### *Exhibition Hall Booth: International AIDS Vaccine Initiative*

**Details:** Stand E-434 in the Exhibition Hall

### *Exhibition Hall Booth: PATH*

**Details:** Stand E-451 in the Exhibition Hall

## SATURDAY, JULY 17

**Building Young and Early-Career Investigators capacity to engage community stakeholders and advance HIV prevention research: An OCTAVE Workshop on the UNAIDS and AVAC Good Participatory Practice Guidelines Satellite**

**Time:** Saturday 17 July 8:30-18:00 (closed session)

**Summary:** Organized by the Enterprise in collaboration with UNAIDS and AVAC, this workshop will focus on application of the Good Participatory Practice (GPP) guidelines for new investigators engaged in biomedical HIV prevention research, with a focus on HIV vaccines.

**HIV Testing: Global Challenges, Global Strategies, Global Impact  
Pre-Conference Symposium**

**Venue:** Radisson Blu Palais Hotel Vienna, Parkring 14-16

**Time:** Saturday 17 July, 8:30-16:30

**Summary:** What is the current role of HIV Screening/Testing in the prevention of HIV transmission in the global AIDS epidemic? This one-day pre-conference symposium will gather experts to discuss the challenges, strategies, ethical issues, public policies, and cost effectiveness of HIV screening and testing as prevention tools in both the developed and developing worlds.; For more information and to register (which is required), visit <http://chipts.ucla.edu/hivtesting>.

**Organizer(s):** UCLA Center for HIV Identification, Prevention, and Treatment Services (CHIPTS) with support from National Institute of Mental Health and the Ford Foundation.

**Be Heard!: Global Forum Global Forum on MSM & HIV  
Pre-Conference Symposium**

**Venue:** Vienna University of Economics and Business

**Time:** Saturday 17 July, 8:00-21:00

**Details:** One-day preconference event

**Summary:** The 4th pre-conference to the International AIDS Conference, this one-day event will explore the challenges and best practices in achieving universal access to HIV-related prevention, care, treatment, and support services for sexual minority communities worldwide. Due to the overwhelming response, general pre-registration is closed; please contact [aids2010@msmgf.org](mailto:aids2010@msmgf.org) for any inquiries.

**Organizer(s):** Global Forum Global Forum on MSM & HIV (MSMGF)

## SUNDAY, JULY 18

**The Search for an HIV Vaccine: Where are we, where are we going, and how can we get there faster? (SUSA14)  
Non-Commercial Satellite**

**Venue:** Mini Room 6

**Time:** Sunday 18 July, 11:15-13:15

**Summary:** This session will include a review of the last 25 years of AIDS vaccine research and development; a panel discussion on the progress that's been made including discussions on next steps following the RV144 Thai prime-boost study results and in developing the next generation of vaccine candidates for testing; an update on the Global HIV Vaccine Enterprise Scientific Strategic Plan for the field; and a panel discussion on the way forward, which will consider some of the cross-cutting considerations such as industry engagement, developing world infrastructure, community engagement, opportunities for young and early-career investigators, mobilizing resources and building clinical trial and regulatory capacity.

**Organizer(s):** African AIDS Vaccine Programme; AVAC; AIDS Vaccine Asian Network; Canadian HIV Vaccine Initiative; Global HIV Vaccine Enterprise; HIV Vaccine Trials Network; International AIDS Vaccine Initiative (IAVI); South African AIDS Vaccine Initiative; US Military HIV Research Program.

**Global Partnerships in AIDS Vaccine Research (SUSS01)****Special Session****Venue:** Session Room 2**Time:** Sunday 18 July, 13:30-15:00

**Summary:** This session aims to give the audience a review on how different actors and partnerships across the world are helping to drive progress in AIDS vaccine research. The session aims to highlight partnership in doing research, in research capacity building, in shaping policies, in community engagement, and in mobilizing leadership. These partnerships cross the divide between North and South, and East and West. The session will clarify to the audience that AIDS vaccine research is not just a matter of science and researchers; it will highlight opportunities to different parties around the world on how they can also engage in this effort.

**Clever dicks and FC2: Marketing FC2 female condoms in men (SUSA24)****Commercial Satellite****Venue:** Mini Room 3**Time:** Sunday 18 July, 13:30-15:30

**Summary:** In this satellite session SUPPORT brings together a group of marketing experts from a range of private and public sector agencies to facilitate a workshop to develop a promotional campaign for targeting men with female condoms. For many years male condom use has been marketed not only to men but also to women. In contrast, the female condom has been marketed only to women. Yet it is often the case that men make the decisions regarding the use or otherwise of protection during sex. So why don't we market female condoms instead of using no protection at all? SUPPORT together with Michael Chommie from PSI Zimbabwe would like to explore the audience's idea on developing a campaign for men to use the female condom. With expert guidance from a range of marketing agencies and communication experts such as Durex, MTV, BBC World Service Trust, and PSI the audience, with assistance from the panel, will develop campaigns for marketing female condoms to men.

**The Promise and Perils of ARV-based prevention: Making it a reality on the ground (SUSA42)****Non-Commercial Satellite****Venue:** Mini Room 6**Time:** Sunday 18 July, 15:45-17:45

**Summary:** ARV-based prevention, including oral PrEP and ARV-based clinical trials demonstrate efficacy among some populations, formidable challenges remain to demonstrate if effectiveness and feasibility. This session will provide an opportunity for various stakeholders to discuss what needs to happen beyond the current research, including additional research proprieties (such as other potential PrEP candidates and intermittent dosing strategies) and the operational, financial and ethical issues that will need to be addressed in order to translate positive safety and efficacy findings into delivery programmes that will have a public health impact at the country level. The session is designed to initiate debate and dialogue on the opportunities and challenges of ARV-based prevention, what is needed and how ARV-based prevention fits into the broader landscape of HIV prevention and treatment.

**Organizer(s):** AVAC and partners**MONDAY, JULY 19****Building on Success: A Roadmap for HIV Prevention (MOSS01)****Special Session****Venue:** Session Room 1**Time:** Monday 19 July, 13:30-14:00

**Summary:** Concerted global action has transformed the HIV and AIDS response into a top health and humanitarian priority. Now, the world has an historic opportunity to build on success: we must continue expanding treatment while charting a course to intensify prevention and dramatically reduce new HIV infections. Speakers in this session will include Bill Gates, co-chair of the Bill & Melinda Gates Foundation, followed by questions from the audience.

***PUMA: Designing an HIV prevention package for MSM in the Americas*****Venue:** Hotel Wandl, Petersplatz 9 Tel +43-1-534-55-0**Time:** Monday 19 July, 18:30-20:00

**Summary:** To raise awareness about the Prevention Umbrella for MSM in the Americas (PUMA), a planning grant to build a trial that will test a combination of HIV prevention interventions. The session will provide background on the PUMA project, and ask for feedback on building an attractive and impactful prevention package. Space is limited, please RSVP to [jennifer.sarche@sfdph.org](mailto:jennifer.sarche@sfdph.org).

***Prevention Now: Female Condoms and Tools for Use, Programming, and Advocacy for Universal Access (MOGS07) Global Village Workshop*****Venue:** GV Session Room 2**Time:** Monday 19 July, 16:30-18:00

**Summary:** Female condoms are the only HIV/STI and pregnancy prevention tool available for use today that is designed to be initiated by women. Despite their many benefits and advantages, female condoms remain largely underfunded, inaccessible, and underused because of a lack of political will and effective programming. This workshop will equip participants with the knowledge and skills to correctly use the female condom. The workshop will also provide with advocacy tools to urge donors and governments to invest in universal access to female condoms.

## TUESDAY, JULY 20

***Lessons Learned: Promoting HIV Vaccines in Light of Existing Knowledge and Practices from Previous Public Health Interventions (TUSA04) Non-Commercial Satellite*****Venue:** Mini Room 3**Time:** Tuesday 20 July, 7:00-8:30

**Summary:** To gain an international perspective on public health interventions among communities at high risk for HIV infection that could inform future HIV vaccine uptake. The satellite will bring together three panelists to discuss their experiences in these communities. Learn more about this event by visiting [http://www.avac.org/CAS\\_english](http://www.avac.org/CAS_english) or [http://www.avac.org/CAS\\_french](http://www.avac.org/CAS_french)

***Tuesday Plenary (TUPL01) Plenary*****Venue:** Session Room 1**Time:** Tuesday 20 July, 09:00-10:30**Summary:** Presentations in this session include:

- New Concepts in HIV/AIDS Pathogenesis: Implications for Interventions, Anthony Fauci, United States
- Universal Access: Treatment and Prevention Scale-up, Aaron Motsoaledi, South Africa

***Update on Microbicides (TUSS05) Special Session*****Venue:** Session Room 7**Time:** Tuesday 20 July, 13:00-14:00

**Summary:** This session will provide an update of the current state of microbicide development. Speakers will provide updates on microbicide development, safety and efficacy data from CAPRIS 004 and discuss implications of the CAPRISA 004 trial results for the microbicide and Pre-Exposure Prophylaxis (PrEP) field.

**Prevention of Sexual Transmission of HIV (TUPDC2)****Oral Poster Discussion****Venue:** Mini Room 4**Time:** Tuesday 20 July, 13:00-14:00**Summary:** Presentations in this session:

- Baseline findings from the SASA! study: a cluster randomized controlled trial to assess the impact of a community focused violence and HIV prevention programme in Uganda
- A systematic review of couples-based behavioral interventions associated with HIV prevention
- Models to increase volumes and efficiency (MOVE) in Zimbabwe's male circumcision program
- Rollout of voluntary medical male circumcision for HIV prevention in Kenya: one year and counting
- Community monitoring of medical male circumcision for HIV prevention and its impact on women: findings from a five-country pilot in Kenya, Namibia, Swaziland, South Africa, and Uganda
- A model for the roll-out of comprehensive adult male circumcision services in African low-income settings of high HIV incidence: the Bophelo Pele project (ANRS-12126)

**HIV Vaccines – Quo Vadis? (TUSY06)****Symposium****Venue:** Session Room 3**Time:** Tuesday 20 July, 14:30-16:00

**Summary:** The objective of this session is to provide attendants with a brief update on recently completed, large-scale vaccine trials. This session will provide delegates with an informed assessment of the respective value of the diverse approaches which will guide future vaccine design. The session will be comprised of presentations focusing on: 1) the Thai trial (RV 144), ii) T cell vaccine trials and iii) a critical reflection of these and other strategies currently under investigation. The presentations will be followed by a 30-minute podium discussion which will focus on three provocative questions: 1) Was the Thai trial (RV 144) indeed a success or is transient protection all we can gain from this approach? 2) How can T cell vaccines be resurrected? 3) Small scale or large scale: which vaccines trials and which approaches will most effectively move vaccine development forward?

**Advances in Vaccine Development (TUAA01)****Oral Abstract Session****Venue:** Session Room 3**Time:** Tuesday 20 July, 16:30-18:00**Get Ahead of the Game: Your Future Prevention Choices (TU)****Global Village Workshop****Venue:** Women's Networking Zone (in Global Village)**Time:** Tuesday 20 July, 17:15-18:30

**Summary:** Within the next two decades, young women may well be positioned to demand access to oral pre-exposure prophylaxis (PrEP), topical microbicides, vaccines, expanded treatment for HIV-positive people to prevent transmission of the virus, additional female condom models and possibly additional tools. To prepare, young women and men need information about what their future prevention choices may look like and how, as advocates, they can play a role in influencing the development of these new tools and ensuring future access for all who need them. This session will use an interactive "TV game show" format to provide this information and generate lively discussion among participants about what characteristics they want new prevention tools to have, what kinds of tools might be most acceptable in their own communities and how they can advocate for the development of such tools—and rapid access to those that are proven to work.

**Organizer(s):** International AIDS Vaccine Initiative (IAVI), Global Campaign for Microbicides and AVAC

### *Using Antiretrovirals to Prevent HIV: Implications of the CAPRISA 004 tenofovir-gel microbicide trial results (TUSA24) Non-Commercial Satellite*

**Venue:** Mini Room 10

**Time:** Tuesday 20 July, 18:30-20:30

**Summary:** The Global Campaign for Microbicides in partnership with CAPRISA and Treatment Action Campaign invites you to join an exciting, topical, and interactive debate on the implications of the outcomes of the CAPRISA 004, the first ARV-based candidate microbicide trial. The results of the CAPRISA 004 trial testing tenofovir gel as a vaginal microbicide will be announced on Tuesday 20 July at 1pm at AIDS 2010, Vienna. The Tuesday evening satellite aims to further explore the results with an in-depth discussion engaging the study's two principal investigators. Leading scientists and advocates will debate the findings and their implications on the international HIV-biomedical prevention research agenda. They will explore the potential impact of microbicides on the HIV epidemic and ask the important question: what do these results mean for women?

**Organizer(s):** Global Campaign for Microbicide

## WEDNESDAY, JULY 21

### *Wednesday Plenary (WEPL01)*

#### *Plenary*

**Venue:** Session Room 1

**Time:** Wednesday 21 July, 09:00-10:30

**Summary:** Presentations in this session:

- Anti-HIV Drugs for Prevention, Bernard Hirschel, Switzerland
- A Proposal for Change: Managing Patents for Access to AIDS Medicines for All, Ellen 't Hoen, Switzerland
- ART Advances: Into the Next Decade, James Hakim, Zimbabwe

### *Youth Networking Zone*

#### *Global Village Workshop*

**Venue:** Women's Networking Zone (in Global Village)

**Time:** Wednesday 21 July, 13:00-14:30

**Summary:** Within the next two decades, young people may well be positioned to demand access to oral pre-exposure prophylaxis (PrEP), topical microbicides, vaccines, expanded treatment for HIV-positive people to prevent transmission of the virus, additional female condom models and possibly additional tools. To prepare, youth need information about what their future prevention choices may look like and how, as advocates, they can play a role in influencing the development of these new tools and ensuring future access for all who need them. This session will use an interactive "TV game show" format to provide this information and generate lively discussion among participants about what characteristics they want new prevention tools to have, what kinds of tools might be most acceptable in their own communities and how they can advocate for the development of such tools—and rapid access to those that are proven to work.

***Use of Antiretrovirals for Prevention: PrEP, PEP and ART (WESY07)***  
***Symposium***

**Venue:** Session Room 6

**Time:** Wednesday 21 July, 14:30-16:00

**Summary:** Despite years of prevention efforts, HIV incidence has been inadequately controlled and the HIV/AIDS epidemic remains a global public health crisis. The global response has not been sufficient and the current economic crisis threatens recent gains. Given the gravity of the situation, it is not surprising that the question of how best to use antiretroviral treatment (ART) for prevention has emerged. There is increasing evidence that ART has an effect on both horizontal and vertical HIV transmission, and that it reduces mortality in TB/HIV co-infection. Some experts believe that the implementation of voluntary universal testing programmes, with immediate initiation of ART for individuals who test positive, could significantly reduce HIV incidence. However, expert evaluation and further research are required to assess this novel approach, evaluate its appropriateness and feasibility, and define the requirements for public health decision-making on how to best use ART for prevention. The benefits of antiretroviral drugs can also be extended further into prevention for HIV-negative individuals through antiretroviral pre- and post-exposure prophylaxis. A number of clinical trials to study the effectiveness of pre-exposure prophylaxis are ongoing and results will most likely be available before data from planned field trials on the use of universal test and treat (for HIV-positive individuals). This session will explore the potential synergies of the use of antiretrovirals for HIV-positive and HIV-negative individuals.

***Beyond the Scoop: Skills Building for Journalist and CBOs/NGOs in Interpreting and Communication Trial Results for New HIV Prevention Technologies (WEWS204009)***  
***Community Skills Development Workshop***

**Venue:** Mini Room 10

**Time:** Wednesday 21 July, 14:30-18:00

**Summary:** In order to facilitate meaningful community engagement in HIV vaccine, microbicide and other prevention efforts, this workshop aims to increase the knowledge base of new prevention technologies (NPTs) among workshop participants, improve their NPT-related communication skills, and increase their prevention research literacy. The workshop will include critical analysis of past media coverage of NPT trials (including microbicides, vaccines, pre-exposure prophylaxis and male circumcision), and will be relevant to journalists and CBOs/NGOs interested in NPTs.

***ART for Prevention: What are the Implications? (WEBS02)***  
***Bridging Session***

**Venue:** Session Room 1

**Time:** Wednesday 21 July, 16:30-18:00

**Summary:** If it is scientifically true that provision of ART can reduce HIV transmission in addition to reducing HIV morbidity and mortality, including a marked impact on the TB co-epidemic, what are the implications for policy and programmes? Experts from civil society, the WHO and local government will come together in this session to discuss this potentially massive paradigm shift to HIV prevention and treatment. Panelists will address the programmatic considerations of using ART for prevention such as cost, human resource needs and health systems capacity, human rights and ethical considerations, including the importance of civil society input into clinical trials and operational research, and community perspectives on the feasibility and desirability of using ART for prevention in practice. Panelists will also discuss the implications of ART for prevention for scale-up toward universal access.

**38 million by 2015: Strategies for the scale-up of male circumcision services (WESA18)****Non-Commercial Satellite****Venue:** Mini Room 4**Time:** Wednesday 21 July, 18:30-20:30

**Summary:** Recent health impact models have shown that maximize the impact of male circumcision (MS) on the HIV/AIDS epidemic, a massive effort to scale-up in East and to inform how program implementers might meet the challenge of conducting millions of MCs in the coming years. Topics will include: understanding the costs, savings and impact of rapid MS service scale-up; implementing models of volume and efficiency (MOVE) to maximize site performance; designing communications to create sustained, informed demand for MC; integrating neonatal MC services to reach male newborns; deploying new technologies to improve efficiencies (Shang Ring); and, expanding access through mobile services. Discussants will provide recommendations and explain the policy implications of rapid MC service scale-up.

**Organizer(s):** PSI and FHI**Issues and challenges of community-based research****Non-Commercial Satellite****Venue:** Mini Room 10**Time:** Wednesday 21 July, 18:30-20:30

**Organizer(s):** AIDES, ANRS, CHAIRE, CIHR center for REACH in HIV/AIDS, Coalition Plus, COCQ-SIDA, Groupe Sida Geneve, Reseau Francophone de Recherche Communautaire VIH/SIDA, Sidaction, UQAM

**THURSDAY, JULY 22****Thursday Plenary: Combination HIV Prevention: What's New? (THPL0102)****Plenary****Venue:** Session Room 1**Time:** Thursday 22 July, 09:00-10:30**Summary:** Presentations in this session include:

- Combination HIV Prevention: What's New?, Carlos Caceres, Peru

**Advocating for Women-Centered HIV Prevention Technologies and Environments****Skills Building Workshop****Venue:** Mini Room 8**Time:** Thursday 22 July, 11:00-12:30

**Summary:** Women and adolescent girls are acutely affected by HIV and AIDS. Despite this, woman-initiated and controlled prevention options remain largely inaccessible or still in development. In addition to prevention technologies, structural factors such as gender inequality, economic security, and public policy also shape whether women can exercise agency in protecting themselves. Civil society advocacy that targets local and international decision-makers is critical for expanding access to existing and future prevention options, and policy advocates and program practitioners have important and complementary roles in advocacy efforts. In this workshop, experienced facilitators will equip participants with skills and strategies to advocate for structural HIV prevention interventions and access to the full range of woman-initiated prevention options.

**Organizer(s):** AVAC, CHANGE, UNFPA, Pangaea, World YWCA**Scaling Up Male Circumcisions: From Research to Practice (THAC01)****Oral Abstract Session****Venue:** Session Room 4**Time:** Thursday 22 July, 11:00-12:30

***Understanding HIV Transmission Mechanisms: Microbicides and PrEP (THBS03)***  
***Bridging Session***

**Venue:** Session Room 1

**Time:** Thursday 22 July, 16:30-18:00

**Summary:** Understanding factors and mechanisms, cellular pathways, viral features and immune interaction of mucosal HIV transmission should provide important insight to design prevention methods to interrupt transmission. Animal and human studies aiming at blocking mucosal HIV transmission including microbicides and pre-exposure prophylaxis (PrEP) are ongoing. Outcomes of such studies may reshape the landscape of HIV prevention programmes. One of the most promising prevention technologies currently in trials are microbicides which contain antiretrovirals (also referred to as topical PrEP) and oral antiretroviral PrEP or a combination of both. Results of microbicides/PrEP trials are likely to begin appearing in late 2010 and early 2011. Research and development of novel prevention technologies should take into account ethical considerations and involvement of communities in study design. The session will also address challenges and limitations encountered during clinical trials from a community perspective.

***New HIV Prevention Methods – Maximizing the Impact (THSA48)***  
***Non-Commercial Satellite***

**Venue:** Mini Room 4

**Time:** Thursday 22 July, 18:30-20:30

**Summary:** This session will convene global HIV prevention leaders to identify and propose solutions to the toughest questions facing public health funders, policymakers and practitioners about the investment, planning and scale-up of the newest HIV prevention methods. How do we best target research and development resources to maximize impact? Once efficacy of an intervention is established, how do we assure the greatest HIV prevention impact is achieved? What can we learn from past experience and current programs to guide the development and scale-up of new and near-future prevention technologies?

**Organizer(s):** FHI